Northeast Pharmaceutical Group 過去の業績
過去 基準チェック /16
Northeast Pharmaceutical Group has been growing earnings at an average annual rate of 35.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 1.5% per year. Northeast Pharmaceutical Group's return on equity is 6.8%, and it has net margins of 4.3%.
主要情報
35.5%
収益成長率
33.8%
EPS成長率
Pharmaceuticals 業界の成長 | 10.9% |
収益成長率 | 1.5% |
株主資本利益率 | 6.8% |
ネット・マージン | 4.3% |
前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
Northeast Pharmaceutical Group's (SZSE:000597) Weak Earnings May Only Reveal A Part Of The Whole Picture
Oct 30It's A Story Of Risk Vs Reward With Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)
Aug 07These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely
May 25Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Apr 05収支内訳
Northeast Pharmaceutical Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Sep 24 | 7,973 | 347 | 2,056 | 108 |
30 Jun 24 | 7,905 | 380 | 2,066 | 108 |
31 Mar 24 | 7,829 | 346 | 2,270 | 101 |
31 Dec 23 | 8,243 | 358 | 2,573 | 97 |
30 Sep 23 | 8,643 | 442 | 2,839 | 146 |
30 Jun 23 | 8,895 | 373 | 3,031 | 146 |
31 Mar 23 | 8,810 | 352 | 2,913 | 152 |
01 Jan 23 | 8,809 | 350 | 2,789 | 160 |
30 Sep 22 | 8,609 | 202 | 2,727 | 106 |
30 Jun 22 | 8,555 | 151 | 2,752 | 102 |
31 Mar 22 | 8,478 | 129 | 2,776 | 93 |
31 Dec 21 | 8,145 | 99 | 2,711 | 83 |
30 Sep 21 | 8,003 | 37 | 2,613 | 62 |
30 Jun 21 | 7,671 | 14 | 2,530 | 61 |
31 Mar 21 | 7,465 | 71 | 2,458 | 69 |
31 Dec 20 | 7,384 | 12 | 2,453 | 74 |
30 Sep 20 | 7,659 | -1 | 2,751 | 76 |
30 Jun 20 | 7,833 | 113 | 2,784 | 74 |
31 Mar 20 | 8,026 | 97 | 2,901 | 73 |
31 Dec 19 | 8,220 | 174 | 3,014 | 64 |
30 Sep 19 | 7,898 | 214 | 2,880 | 137 |
30 Jun 19 | 7,828 | 198 | 2,823 | 154 |
31 Mar 19 | 7,622 | 200 | 2,724 | 148 |
31 Dec 18 | 7,467 | 195 | 2,581 | 145 |
30 Sep 18 | 7,102 | 196 | 2,443 | 73 |
30 Jun 18 | 6,659 | 196 | 2,214 | 72 |
31 Mar 18 | 6,204 | 160 | 1,987 | 62 |
31 Dec 17 | 5,676 | 119 | 1,740 | 58 |
30 Sep 17 | 5,271 | 98 | 1,470 | 26 |
30 Jun 17 | 5,176 | 60 | 1,416 | 0 |
31 Mar 17 | 5,016 | 39 | 1,318 | 0 |
31 Dec 16 | 4,814 | 24 | 1,236 | 0 |
30 Sep 16 | 4,581 | -156 | 1,204 | 0 |
30 Jun 16 | 4,122 | -295 | 1,204 | 0 |
31 Mar 16 | 4,031 | -358 | 1,223 | 0 |
31 Dec 15 | 3,834 | -384 | 1,153 | 0 |
30 Sep 15 | 4,006 | -194 | 1,078 | 0 |
30 Jun 15 | 4,092 | -77 | 1,009 | 0 |
31 Mar 15 | 4,223 | -8 | 1,039 | 0 |
31 Dec 14 | 4,333 | 87 | 1,077 | 0 |
30 Sep 14 | 4,260 | -27 | 1,224 | 0 |
30 Jun 14 | 4,199 | -56 | 1,226 | 0 |
31 Mar 14 | 4,022 | -77 | 1,178 | 0 |
31 Dec 13 | 3,871 | -167 | 1,130 | 0 |
質の高い収益: 000597 has a large one-off gain of CN¥206.2M impacting its last 12 months of financial results to 30th September, 2024.
利益率の向上: 000597's current net profit margins (4.3%) are lower than last year (5.1%).
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 000597's earnings have grown significantly by 35.5% per year over the past 5 years.
成長の加速: 000597's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
収益対業界: 000597 had negative earnings growth (-21.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
株主資本利益率
高いROE: 000597's Return on Equity (6.8%) is considered low.